Safety and Tolerability of RPE Stem Cell-derived RPE(RPESC-RPE) Transplantation in Patients With Dry Age-related Macular Degeneration (AMD)

Recruiting now · Phase 1/Phase 2

Conditions studied: Dry Age-related Macular Degeneration

In brief

The main objective of the study is evaluation of the safety and tolerability of RPESC-RPE-4W as therapy for dry AMD.

Key facts

Study ID
NCT04627428
Run by
Luxa Biotechnology, LLC
People needed
18
Starts
2022-04-05
Expected to finish
2026-12-01
Last updated by the study team
2025-10-15

Who can join

Age: 55 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.